Response of histiocytoses to imatinib mesylate: fire to ashes.
Janku
Filip
F
The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Amin
Hesham M
HM
Yang
Dan
D
Garrido-Laguna
Ignacio
I
Trent
Jonathan C
JC
Kurzrock
Razelle
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D031249:Erdheim-Chester Disease / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D016313:Genes, abl / Q000235:genetics; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C426236:ARG tyrosine kinase; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta